A noteworthy investigation centered on CAR-T cells targeting glypican-3 (GPC3), a unique antigen commonly found in advanced HCC cases, revealed impressive antitumor effectiveness, with several patients showing marked tumor reduction and increased survival duration (100). This evidence concerns the gene GPC3 and neoplasm.